HIGH LEVEL OF EXPRESSION OF INGAP

Abstract: Removal of the nucleotide sequence encoding the signal peptide from the INGAP coding sequence allows bacteria to express substantial amounts of INGAP activity. Previous attempts have provided only low yields of INGAP, possibly because the signal sequence of INGAP is toxic to bacteria.

Description: fflGH LEVEL OF EXPRESSION OF INGAP TFΓHNTΓAT, FTELD OF THE INVENTION This invention is related to methods and constructs for achieving high level expression of INGAP, a protein involved in islet cell neogenesis. BACKGROUND OF THE INVENTION Pancreatic islets of Langerhans are the only organs of insulin production by β cells in the body. However, they have a limited capacity for regeneration. This limited regeneration capacity predisposes mammals to develop diabetes mellitus. Thus there is a need in the art of endocrinology for products which can stimulate the regeneration of islets of Langerhans to prevent or ameliorate the symptoms of diabetes mellitus. There are many factors regulating pancreatic β cell mass. (Vinik, et al., Diabetes Reviews 4: 235-263, 1996.) A pancreatic extract called Ilotropin induces β cell regeneration and reverses diabetes. (Rosenberg et al. (1996) Diabetologia 39: 256-262. A gene encoding a protein within Ilotropin has been identified and isolated; the protein is responsible for stimulating islet cell regeneration. (Rafaeloff, R. Abst. 1995, Diabetes 44:15 A.) This protein is called INGAP, and is disclosed in patent applications Serial Numbers 08/401,530, 08/709,662, and 60/006,271. The disclosure of these applications is expressly incorporated herein. Despite the knowledge of the complete nucleotide sequence of the INGAP gene, expression of the protein has been limited. Thus there is a need in the art for methods of expressing and isolating large quantities of the INGAP protein. SUMMARY OF THE INVENTION It is an object of the present invention to provide a method of producing biologically active LNGAP protein from a recombinant host cell. It is another object of the present invention to provide a host cell which expresses large amounts of INGAP protein. It is an object of the present invention to provide a recombinant construct for expression of biologically active INGAP protein. Another object of the invention is to provide a method for isolating INGAP protein from a recombinant host cell. These and other objects of the invention are achieved by providing the art with a recombinant construct for expression of biologically active INGAP protein comprising: a first nucleotide sequence encoding amino acids 27 to 175 operably linked to a transcriptional initiation site and a translational initiation site, wherein a second nucleotide sequence encoding a signal peptide is not present immediately 5 1 of said first nucleotide sequence. In another embodiment of the invention a method of producing INGAP activity from a recombinant host cell is provided. The method comprises the steps of: culturing a host cell comprising a recombinant construct comprising a first nucleotide sequence encoding amino acids 27 to 175 operably linked to a transcriptional initiation site and a translational initiation site, wherein a second nucleotide sequence encoding a signal peptide is not present immediately 5' of said first nucleotide sequence; recovering protein from said cultured host cell. In yet another embodiment of the invention a host cell is provided. The host cell comprises a recombinant construct comprising a first nucleotide sequence encoding arnino acids 27 to 175 operably linked to a transcriptional initiation site and a translational initiation site, wherein a second nucleotide sequence encoding a signal peptide is not present immediately 5* of said first nucleotide sequence. These and other embodiments of the invention which will be apparent to those of skill in the art provide a practical source of INGAP protein in amounts suitable for use in preclinical and clinical situations. RRTEF DESCRIPTION OF THE PR A WINGS Figure 1. SDS-PAGE gel of products of bacterial transfection. Bacterial lysate without transfection (CBL), bacterial lysate with transfection (TBL), fractions from Ni-NTA chromatography (eluted at pH6.3 (6.3); pH 5.9 (5.9); and pH 4.5 (4.5) and standards (Std). Figure 2. ECL film of Western blot using INGAP antibody 945-2. Lanes are as didentified in the description to Figure 1. DT7T H ED DESCRIPTION It is a discovery of the present inventors that bacterial expression of INGAP can be achieved at high levels by deleting the coding sequence of the signal sequence of INGAP. While not wanting to be bound by any particular theory or mechanism of action, applicants believe that the signal sequence is toxic to bacterial hosts. The signal sequence comprises amino acids 1 to 26 as shown in SEQ ID NO:l. In the constructions tested, the 5' untranslated region comprising nucleotides 1-16 has also been deleted. This deletion may also contribute to the increase in expression which has been observed. Another aspect of the constructions which applicants have found to be exceedingly useful is an inducible transcription initiator. Suitable inducible transcription initiators include those inducible by isopropyl thiogalactoside (IPTG), such as the lac promoter/operator, as well as others which are known in the art. According to still another aspect of the constructions which applicants have developed, a histidine tag can be engineered to be on the protein. The histidine tag can simplify processing and purification. A histidine tag is a stretch of histidine residues which are appended to a protein, usually by genetic engineering. Preferably the tag comprises between 3 and 12 histidine residues. They may be contiguous or interrupted by other residues. The histidine tag may be appended to the N-terminal or to the C-terminal end of the protein to minimize disruption of protein function. Methods for making and utilizing histidine tags are known in the art. The oligohistidine can be used as an affinity moiety using a metal chelate, such as nickel-NTA (N-(5-aιrιino-l-carboxypentyl)-iminodiacetic acid) as the other affinity partner. A recombinant construct according to the invention, is any DNA molecule which has been engineered so that two segments of DNA are adjacent to each other which are not adjacent to each other in nature. Preferably such engineering is performed in vitro, although in vivo engineering can also be performed. The construct may be a plasmid, phage, virus, transposable element, minichromosome, or other element, as is suitable for the desired application. The coding sequence of amino acid residues 27-175 of INGAP protein are included in the constructs. Preferably the entire signal sequence is deleted. However, it is possible that only a portion of the signal sequence must be deleted to obtain excellent expression. Thus some portion of the signal sequence might be retained in the constructs. Deletion of the 5 1 untranslated region, nucleotides 1-16, is also desirable. However, it is not known if this is necessary to achieve excellent expression. Thus the 5 1 untranslated region may be retained in some constructs without departing from the spirit of the invention. A host cell according to the invention can be transfected or transformed with a recombinant construct according to the present invention. The host may be a bacterial, yeast, insect or mammalian cell.- Selection of suitable promoters and translational initiators for use in the appropriate host cell is well within the ken of those of skill in the art. Host cells may be transformed, transfected, mated or infected with the recombinant host cell of the present invention. Culturing of host cells can be performed using techniques and media which are well known in the art. Again, a suitable medium and technique can be selected by the ordinarily skilled artisan. The above disclosure generally describes the present invention. A more complete understanding can be obtained by reference to the following specific examples which are provided herein for purposes of illustration only, and are not intended to limit the scope of the invention. RYA PT .R 1 This example describes the experimental design employed. We generated a new INGAP cDNA by PCR which excluded the 5' UTR region (nucleotides 1-16 in SEQ ID: 1) and the signal peptide (nucleotides 17-94) and created two new restriction enzyme recognition sites enabling the insertion of the new construct into a new pQE-31 expression vector. This new ligated construct was transformed into TOP10F 1 competent cells (E. coli host strain from Invitrogen). The positive clones were identified, verified by restriction enzyme digestion and the DNA isolated. The DNA was now transformed into a different competent E. coli strain, M15(pREP4) and expression of the protein was induced by IPTG (isopropyl-beta, D-thiogalactopyranoside) which inhibits the repressor, facilitating expression of the protein from the M15 promoter/operator. The reason for the intermediate transformation of the ligated material into TOP10F' is that these cells are highly competent increasing the odds of getting insert positive colonies. The M15(pREP4) cells that were used for protein expression do not attain competency levels high enough to guarantee transformation of the ligation products. The resultant plasmid DNA obtained from the transformation of the TOPI OF' was sufficient to enhance the transformation of the M15(pREP4) cells. The His-tagged protein was isolated by Ni +2 agarose affinity purification. We used a PCR approach to generate a new INGAP cDNA which excludes the 5 ' UTR region (nucleotides 1-16 in SEQ ID NO: 1) and the signal peptide. The sequence ( SEQ ID NO: 1 ) that has been excluded is as follows: (the bolded area represents the sequence of the signal peptide) CTGCAAGACAGGTACC ATG ATG CTT CCC ATG ACC CTC TGT AGG ATG TCT MET MET Leu Pro MET The Leu Cys Arg MET Ser TGG ATG CTG CTT TCC TGC CTG ATG TTC CTT TCT TGG GTG GAA GGT Trp MET Leu Leu Ser Cys Leu MET Phe Leu Ser Trp Val Glu Gly EXAMPLE 2 This example describes the use of polymerase chain reaction to synthesize INGMAT (construct which lacks the signal peptide sequence, i.e. , which encodes the mature protein). Oligonucleotide design: Oligonucleotides for PCR were designed to incorporate restriction enzyme recognition sites at their respective 5' ends. The oligonucleotide designed for the 5' end of the gene incorporates a Bam HI site followed by 20 nucleotides corresponding to the N-terminus of the mature protein. The oligonucleotide designed for the 3' end incorporates an Xho I site followed by 20 untranslated nucleotides. The PCR product generated from these primers contains the mature INGAP sequence and the native protein termination codon. The following is the sequence of the oligonucleotides used: 5' of INGAP (SEQ ID NO: 2 ) 5'- CCGCGGATCCCGAAGAATCTCAAAAGAAACT- 3' 3' of INGAP ( SEQ ID NO: 3) 5'- GACCGGCTCGAGTGCTCTTCCTGAGTGAATCC -3' PCR of INGMAT Reaction conditions Template: (50 ng INGAP original cDNA removed from pCDNA3) 5 μl MgCl 2 : 4 μl 10 X PCR buffer 5 μl dATP 1 μl dCTP 1 μl dGTP 1 μl dTTP l l 5' primer 1 μl 3' primer 1 μl H 2 O 29 μl Taq polymerase 1 μl total volume = 50 μl cycle parameters A) 2 min at 95°C B) 30 cycles of (1 min 95°C, 1 min 55°C, 1 min 72°C) C) 7 min at 72°C D) 4°C until removed from thermal cycler. The PCR products were then electrophoresed on a 5% PAGE in TBE. Ethidium bromide stained PCR products corresponding to the expected size for the construct were cut from the gel. The gel fragments were electro-eluted into 0.5 ml of TBE, precipitated with 50 μl 3 M sodium acetate and 1 ml of isopropanol at -80° C for 20 rnin, centrifuged, washed once with 1 ml of isopropanol, washed once with 1 ml of 70% ethanol, and then dried under vacuum. The dried pellet was resuspended in 50 μl H 2 O and quantified. At the end of this step the sequence of the PCR product that contains both restriction sites minus the signal sequence and 5' UTR was as follows ( SEQ ID NO: 4): 5-CC GCG GAT CCC GAA GAA TCT CAA AAG AAA CTGCCT TCT TCA CGT ATA ACC TGT CCT CAA GGC TCT GTA GCC TAT GGG TCC TAT TGC TATTCA CTG ATTTTG ATA CCA CAG ACC TGG TCT AAT GCA GAA CTA TCC TGC CAG ATG CATTTC TCA GGA CAC CTG GCA TTT CTT CTC AGT ACT GGT GAA ATT ACC TTC GTG TCC TCC CTT GTG AAG AAC AGT TTG ACG GCC TAC CAG TAC ATC TGG ATT GGA CTC CAT GAT CCC TCA CAT GGT ACA CTA CCC AAC GGA AGT GGA TGG AAG TGG AGC AGT TCC AAT GTG CTG ACC TTC TAT AAC TGG GAG AGG AAC CCC TCT ATT GCT GCT GAC CGT GGTTATTGT GCA GTT TTG TCT CAG AAA TCA GGT TTT CAG AAGTGG AGAGATTTTAATTGTGAA AAT GAG CTT CCC TAT ATC TGC AAATTC AAG GTC TAG GGC AGTTCT AATTTC AAC AGC TTG AAA ATA TTA TGA AGC TCA CAT GGA CAA GGA AGC AAG TAT GAG GAT TCA CTC AGG AAGAGC ACT CGA GCC GGT C -3 * ❖ The bolded areas represent the primers. FY AMPLE 3 This example describes the creation of a plasmid containing the expression construct. Restriction enzyme digestion of the INGMAT PCR product and the pQE-31 vector. We performed two parallel restriction enzyme digestion reactions using 2.5 μg of both the INGMAT PCR product and pQE-31 vector. INGMAT was digested with Bam HI and Xho I simultaneously in a 30 μl volume. PQE-31 was digested with Bam HI and Sal I simultaneously in a 30 μl volume. Both digestion reactions were carried out at 37 °C for a period of 4 hours. After the reactions were completed, 400 ng of each was electrophoresed on a 1.5 % agarose gel and stained with ethidium bromide to assure complete digestion. The remainder ( " 2. lug) of both digestion reactions were passed over a sepharose G-50 to remove the small DNA fragments followed by two equal volume phenol extractions. The extracted DNA was then precipitated with 2 volumes of ethanol and 1/10 volume 3 M sodium acetate at -80° C for 20 minutes, centrifuged, washed twice with 70% ethanol and dried under vacuum. The pellets were resuspended in 25 μl H 2 O and quantified. The pQE-31 expression system was purchased from QIAGEN Inc. Chatsworth, CA. Ligation of INGMAT into pQE-31 INGMAT (Bam Hl/Xho I) and pQE-31(Bam Hi/Sal I) have compatible ends suitable for ligation . As a result of the ligation the Sal I restriction site in the vector will be eliminated. Ligation conditions using a 2: 1 vector to insert molar ratio. pQE31(vector) 517 ng 9 μl INGMAT (insert) 165 ng 2.5 μl 10 X ligation buffer 5 μl 10 mM rATP 5 μl T4 Ligase 4u 1 μl H 2 O 27.5 μl final volume = 50 μl , The ligation reactions were incubated at 4° C for 16 hours. Transformation of the ligation reaction products into TOP10F' competent E. coli We removed 5 μl of the ligation reaction into 100 μl of competent TOPI OF' cells, (TOP10F 1 cells were purchased from Invitrogen, San Diego, CA) with 0.5 μl of 500mM β-mercaptoethanol and incubated on ice for 30 minutes, heat shocked for 45 seconds at 42° C, and recovered on ice for 2 minutes. Then we added 1 ml of prewarmed S°C media and incubated at 37° C with shaking at 225 rpm for 1 hour followed by plating all the transformation reaction on LB broth agar plates containing 100 μg/ml ampicillin. Selection of transformants. Colony containing plates were lifted onto Nytran membranes. The colonies were lysed with 0.5 M NaOH, neutralized, and the resultant DNA bound to the membrane by baking at 80 °C for 1 hour. The membranes were then hybridized in 50% formaldehyde, 5 X SSPE at 50°C for 16 hours with 3 x 10 6 cpm/ml of 32 P random primed INGAP cDNA. The membranes were washed at high stringency and exposed to X-ray film. Positive colonies were matched up to the X-ray film and grown up in 3 mis of LB with ampicillin . DNA isolation from positive transformants. DNA was isolated from the small cultures using alkaline lysis, phenol extracted, precipitated, dried, and resuspended in 50 μl H 2 O. A small aliquot of each of the isolated DNA were digested with Bam HI and Hind III to release inserts. The digested DNAs were electrophoresed on 1.5% agarose and stained with ethidium bromide and positive inserts identified at approximately 510 bp size range. We took four of the insert containing plasmids and incubated them in the presence of RNAse to remove any residual bacterial RNA. Transformation of the ligation products into M15(pREP4) competent E. coli. We removed 5 μl of the cleaned DNA isolated in section HE and transfer it into 100 μl of M15(pREP4) competent cells. The mixture was incubated on ice for 30 minutes, heat shocked for 45 seconds at 42°C, and recovered on ice for 2 minutes. 1 ml of prewarmed SOC media was added and incubated at 37 °C with shaking at 225 rpm for 90 minutes. All of the transformation reaction was plated on LB broth agar plates containing 100 μg/ml ampicillin and 25 μg/ml kanamycin. Selection of transformants for INGMATHIS (INGMAT plus a six-histidine tag) protein production Eight colonies were picked and grown up in LB with ampicillin. DNA was isolated from the small cultures using alkaline lysis extraction procedures, phenol extracted, precipitated, dried, and resuspended in 50 μl H 2 O. A small aliquot of each of the isolated DNA were digested with Bam HI and Hind III to release inserts. The digested DNA was run on 1.5% agarose gel and visualized by staining with ethidium bromide. Several of the transformants which demonstrated the plasmid with inserts of the correct size as well as the presence of the pREP4 plasmid were stored in 50% glycerol at -80° C to be used for protein production. EXAMPLE 4 This example describes the denaturing metal affinity protein chromatography isolation of the his tagged INGAP protein without signal peptide. (Procedure for a 250 ml pINGMATHIS transformed M15(pREP4) culture. pINGMATHIS is the INGMATHIS construct ligated into the pQE-31 vector.) Bacteria growth and protein induction. We grew a 25ml overnight in LB with lOOμg/ml ampicillin and 25μg/ml kanamycin antibiotic. We started a 250 ml LB plus lOOμg/ml ampicillin and 25μg/ml kanamycin culture with 5 ml of the overnight. (1:50) Grown until ABS600= 0.0.75 to 0.9 (actual OD =0.866). Added 5 ml of lOOmM IPTG (2mM final) to induce production of the protein. Continue growing for 4 hours in the case of INGAP. Collected the bacteria and spin at 6000 rpm for 20 minutes, discarded the supernatant. The pellet was frozen until ready to use at -70 C. Ni +2 NTA agarose preparation. Prepare as much as will be needed. (Use 10 ml of the 50% Ni +2 NTA for each 250 ml derived bacterial pellet). Place 16 ml of the 50% slurry into a disposable 50 ml centrifuge tube. Centrifuge for 2 minutes at 800x g and discard the supernatant. Add 42 ml of sterile water, resuspend the resin. Centrifuge for 2 minutes at 800 x G and discard the supernatant. Add 42 ml of sterile water, resuspend the resin. Centrifuge for 2 minutes at 800 x G and discard the supernatant. Add 42 ml of binding/lysis buffer A (6 M Guanidine HC1, 0.1M sodium phosphate, 0.01 M Tris, pH 8.0) and resuspend the resin. Centrifuge for 2 minutes at 800 x G and discard the supernatant. Add 42 ml of binding/lysis buffer A (6 M Guanidine HCL, 0.1M sodium phosphate, 0.01 M Tris, pH 8.0) and resuspend the resin. Centrifuge for 2 minutes at 800 x G and discard the supernatant. Add 42 ml of binding/lysis buffer A (6 M Guanidine HCL, 0.1M sodium phosphate, 0.01 M Tris, pH 8.0) and resuspend the resin. Centrifuge for 2 minutes at 800 x G and discard the supernatant. Bring the total volume up to 10 ml with buffer A. The slurry is now ready for the application of the lysed bacteria. Bacteria lysis and protein isolation. Thaw the bacterial pellet for 15 minutes at room temperature. Resuspend the pellet in 12.5 ml of lysis buffer A. (6 M Guanidine HCL, 0.1M sodium phosphate, 0.01 M Tris, pH 8.0). Transfer the resuspension to a 50 ml centrifuge tube. Freeze the resuspension/lysate at -70 until solid. Thaw at room temperature. Place the lysate on a rotator for 60 minutes at room temperature. Centrifuge the lysate for 15 minutes at 10,000 X G. Collect the supernatant and add the 10 ml of prepared Ni2+NTA. Rotate for 45 minutes. Load the slurry onto a 1.6 cm diameter column and allow to flow through by gravity. Begin Washes. Flow through 50 ml of buffer A. (No need to collect.) Flow through 40 ml of buffer B (8 M Urea, 0.1 M Sodium phosphate, 0.01 M Tris, pH 8.0). ( No need to collect.) but A 280 should be at or near zero before continuing, if not, then wash with more. Wash through 40 ml of buffer C, same as B but pH 6.3. Collect 3 ml fractions. Wash through 40 ml of buffer D, same as B but pH 5.9. Collect 3 ml fractions. Wash through 40 ml of buffer E, same as B but pH 4.5. Collect 3 ml fractions. At this point the protein should be in one of the fractions taken. Read the absorbance at 280 of all the fractions to discern where the protein is. Pool, reduce, and SDS page electrophoresis as necessary. Dialysis In order to purify the expressed protein, we changed the carrier solution of the fraction extracted from the nickel/NTA at pH 4.5 to Tris buffer using dialysis. Dialysis tubing with a molecular weight cut-off of 3000 was prepared by boiling in 5mM EDTA/200 mM sodium bicarbonate for 5 minutes. The tubing was rinsed briefly in deionized water and boiled another 5 minutes in the bicarbonate solution. The tubing was returned to deionized water, covered with aluminum foil and autoclaved for 10 minutes on a liquid cycle. The tubing was handled with latex gloves during the entire procedure. One ml of the protein solution from the nickel/NTA column in 6M guanidine HCl was dialyzed against 4 Uters of 25 mM Tris buffer at pH 8.5 for 12 hours. After dialysis, there were 2 mis of protein solution with a protein concentration of 800 ug/ml. EXAMPLE 5 This example describes analytical techniques confirming the identity of the product. SDS-PAGE In order to test for the overexpression of the INGAP protein, discontinuous denaturing polyacrylamide gel electrophoresis was performed on the dialyzed protein solution using the Hoefer SE250 Mighty Small II apparatus. The separating gel was prepared with 15% acrylamide, 1.35% bis-acrylamide in 375mM Tris buffer at pH 8.8 with 0.05% sodium dodecyl sulfate. Polymerization was induced by addition of 0.05% ammonium persulfate and 20μl TEMED/15 ml solution. The solution was placed in the gel plate apparatus for polymerization. The stacking gel was poured with the same solution, except the Tris buffer was 125mM at pH 6.8, and the acrylamide concentration was 4% . The protein samples were diluted 1: 1 with sample buffer (125 mM Tris-Cl, pH 6.8, 4% SDS, 20% glycerol, and 10% 2-mercaptoethanoι) . The upper and lower tank buffers were identical, containing 25mM Tris, 192 mM glycine and 0.1% SDS at pH 8.3. Two gels were loaded with 20μl each of bacterial lysate without transfection (CBL,368 ug/ml), bacterial lysate with transfection (TBL, 34 lug/ml), the fractions from Ni-NTA chromatography (eluted at pH6.3, 110 ug/ml; pH 5.9, 100 ug/ml; and pH 4.5, 800ug/ml) and standards (Rainbow Markers, Amersham and Dalton Mark- VII, Sigma). Electrophoresis was performed at 20 mA constant current until the dye front entered the separating gel, and at 60 mA constant current until the dye front reached 0.5cm from the bottom. The gels were then removed and one was fixed with 45% methanol/10% acetic acid for one hour, and the other was placed in transfer buffer (25 mM Tris, 192 mM glycine, 20% methanol, pH 8.3) for 20-30 minutes. Silver Staining The fixed gel was equilibrated with 2 changes of 10% ethanol/5% acetic acid for 30 minutes each. The gel was then exposed to a 0.0032N HNO 3 /K2Cr2O7 solution for 5 minutes. The gel was washed in deionized water 3 times for 10 minutes each. The gel was impregnated with silver using O. lg AgNO 3 /50 ml H 2 O for 30 minutes. The silver solution was washed off the gel in deionized water for 5 minutes. The gel was then exposed to a developer solution (29.7 g anhydrous Na2CO 3 in 1 liter H2O with 0.5 ml formalin) in 5 minute intervals between changes until the desired density was reached. The development was stopped with 10% acetic acid, and the gel stored in H 2 O. The gel showed a protein band of approximately 19 kD that was prominent in the bacterial lysate from transfected cells and in the elution fraction from pH 4.5 on nickel/NTA (Figure 1). This protein was not represented in any of the other samples. This is consistent with the size of INGAP protein and with interaction of the inserted histidine tagging region with the nickel/NTA column matrix. Western Blotting Immobilon-P PVDF membrane was wetted with 100% methanol, and equilibrated with transfer buffer for 10 minutes. The gel was removed from transfer buffer and placed on the PVDF membrane. All bubbles between the membrane and the gel were removed. The combination was placed between Whatmann 3mm filter paper wetted with transfer buffer and the whole "sandwich" was placed in the cassette of a Hoefer transfer tank. The cassette was placed in the transfer tank filled with transfer buffer with the gel toward the cathode. The transfer was performed at 12V constant voltage for 18 hours. After transfer, the membrane was placed in a blocking buffer of 0.5M Tris, 2M NaCl and 1% polyethylene glycol with 5% bovine serum albumin and 10% goat serum at room temperature for 1 hour. The membrane was then placed into 20 ml of blocking buffer containing INGAP antibody 945-2 at a dilution of 1:5000 and incubated at room temperature for 1 hour. The membrane was then washed 3 times for 15 minutes each with 50 ml of washing buffer (0.4% Tween-20 in phosphate-buffered saline (PBS) at pH 7.4). The membrane was then incubated for 1 hour at room temperature in washing buffer containing anti-rabbit IgG (whole molecule, Sigma Cat # A-0545) peroxidase conjugate at a 1:160,000 dilution. The membrane was washed 3 times for 5 minutes in 50 ml of 0.2% Tween-20 in PBS, followed by 3 washes of 5 minutes each with 0.1 % Tween-20 in PBS. The blot was revealed using the enzyme cherniluminescence kit from Amersham Corp. , Arlington, IL according to instructions. The ECL blot was exposed to Kodak X-Omat AR-5 X-ray film for 20 minutes. ECL of the blot revealed strong protein recognition of the overexpressed 19 kD proteins in the whole lysate from transfected bacteria (TBL) and the pH 4.5 fraction that were visualized on the SDS-PAGE gels (Figure 2). In addition, there was a protein band recognized in both bacterial lysates at 40 kD, implying that this protein is weakly recognized and is a bacterial protein rather than a product of the transfection. Finally, there was a light band at 14 kD recognized by the antibody in both the transfected bacterial lysate and in the pH 4.5 fraction. This may either be another protein or a lytic fraction of the INGAP protein. Given the engineering done to produce the INGAP protein it is most likely a lytic fraction of INGAP. In summary, we have been able to express INGAP protein in a prokaryotic system by excluding the 5'UTR and the signal peptide and insertion of the new construct into a new vector. The resultant protein is of the predicted molecular size of INGAP monomer and reacts with the antibody to INGAP in a Western analysis. The protein shares with INGAP peptide the ability to induce ductal cell proliferation.

Claims: CLAIMS 1. A recombinant construct for expression of INGAP activity comprising: a first nucleotide sequence encoding amino acids 27 to 175 operably linked to a transcriptional initiation site and a translational initiation site, wherein a second nucleotide sequence encoding a signal peptide is not present immediately 5' of said first nucleotide sequence.- 2. The construct of claim 1 wherein nucleotides 1-16 of SEQ ID NO:l are not present 5' of said first nucleotide sequence. 3. The construct of claim 1 further comprising a third nucleotide sequence encoding a histidine tag. 4. The construct of claim 3 wherein the third nucleotide sequence is immediately 5' or 3 * to said first nucleotide sequence. 5. The construct of claim 1 wherein the transcriptional initiation site is inducible. 6. The construct of claim 1 wherein the transcriptional initiation site is the lac promoter/operator. 7. A method of producing biologically active INGAP protein from a recombinant host cell, comprising the steps of: culturing a host cell comprising a recombinant construct comprising a first nucleotide sequence encoding amino acids 27 to 175 operably linked to a transcriptional initiation site and a translational initiation site, wherein a second nucleotide sequence encoding a signal peptide is not present immediately 5' of said first nucleotide sequence; recovering protein from said cultured host cell. 8. The method of claim 7 wherein the construct further comprises a third nucleotide sequence encoding a histidine tag, and INGAP protein is purified using a nickel affinity matrix. 9. A host cell comprising a recombinant construct comprising a first nucleotide sequence encoding amino acids 27 to 175 operably linked to a transcriptional initiation site and a translational initiation site, wherein a second nucleotide sequence encoding a signal peptide is not present immediately 5' of said first nucleotide sequence.

Inventors: BARLOW SCOTT W, PITTENGER GARY I, RAFAELOFF RONIT, VINIK AARON I, BARLOW, SCOTT, W., PITTENGER, GARY, I., RAFAELOFF, RONIT, VINIK, AARON, I.
Applicants: EASTERN VIRGINIA MED SCHOOL, EASTERN VIRGINIA MEDICAL SCHOOL OF THE MEDICAL COL
Application year: 1997
Main classification: C12N15
IPC codes: C07K1, C07K14, C12N1, C12N5, C12N15, C12P21